Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease

The role of adipose tissue insulin resistance in the pathogenesis of nonalcoholic fatty liver disease (NAFLD) remains unclear. To evaluate this, we measured in 207 patients with NAFLD (age = 51 ± 1, body mass index = 34.1 ± 0.3 kg/m2) and 22 controls without NAFLD (no NAFLD) adipose tissue insulin resistance by means of a validated index (Adipo‐IRi = plasma free fatty acids [FFA] x insulin [FPI] concentration) and as the suppression of plasma FFA during an oral glucose tolerance test and by a low‐dose insulin infusion. We also explored the relationship between adipose tissue insulin resistance with metabolic and histological parameters by dividing them based on quartiles of adipose tissue insulin resistance (Adipo‐IRi quartiles: Q1 = more sensitive; Q4 = more insulin resistant). Hepatic insulin resistance, measured as an index derived from endogenous glucose production x FPI (HIRi), and muscle insulin sensitivity, were assessed during a euglycemic insulin clamp with 3‐[3H] glucose. Liver fat was measured by magnetic resonance imaging and spectroscopy, and a liver biopsy was performed to assess liver histology. Compared to patients without steatosis, patients with NAFLD were insulin resistant at the level of adipose tissue, liver, and skeletal muscle and had higher plasma aspartate aminotransferase and alanine aminotransferase, triglycerides, and lower high‐density lipoprotein cholesterol and adiponectin levels (all P < 0.01). Metabolic parameters, hepatic insulin resistance, and liver fibrosis (but not necroinflammation) deteriorated as quartiles of adipose tissue insulin resistance worsened (all P < 0.01). Conclusion: Adipose tissue insulin resistance plays a key role in the development of metabolic and histological abnormalities of obese patients with NAFLD. Treatment strategies targeting adipose tissue insulin resistance (e.g., weight loss and thiazolidinediones) may be of value in this population. (HEPATOLOGY 2012)

[1]  F. Anania,et al.  Adiponectin inhibits leptin signalling via multiple mechanisms to exert protective effects against hepatic fibrosis. , 2011, The Biochemical journal.

[2]  K. Cusi,et al.  Role of ethnicity in overweight and obese patients with nonalcoholic steatohepatitis , 2011, Hepatology.

[3]  D. Rockey,et al.  Adiponectin regulation of stellate cell activation via PPARγ-dependent and -independent mechanisms. , 2011, The American journal of pathology.

[4]  P. Scherer,et al.  Adipose tissue remodeling and obesity. , 2011, The Journal of clinical investigation.

[5]  R. Ahima.  Digging deeper into obesity. , 2011, The Journal of clinical investigation.

[6]  D. Goulis,et al.  Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis. , 2011, Metabolism: clinical and experimental.

[7]  L. Luzi,et al.  Prevalence, Metabolic Features, and Prognosis of Metabolically Healthy Obese Italian Individuals , 2010, Diabetes Care.

[8]  J. Hardies,et al.  Pioglitazone in the treatment of NASH: the role of adiponectin , 2010, Alimentary pharmacology & therapeutics.

[9]  Manfred Stommel,et al.  Variations in BMI and Prevalence of Health Risks in Diverse Racial and Ethnic Populations , 2010, Obesity.

[10]  B. Neuschwander‐Tetri.  Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites , 2010, Hepatology.

[11]  K. Cusi.  The Role of Adipose Tissue and Lipotoxicity in the Pathogenesis of Type 2 Diabetes , 2010, Current diabetes reports.

[12]  S. Friedman,et al.  Downregulation of hepatic stellate cell activation by retinol and palmitate mediated by adipose differentiation‐related protein (ADRP) , 2010, Journal of cellular physiology.

[13]  G. Svegliati-Baroni,et al.  From the metabolic syndrome to NAFLD or vice versa? , 2010, Digestive and Liver Disease.

[14]  S. Klein,et al.  Obesity and nonalcoholic fatty liver disease: Biochemical, metabolic, and clinical implications , 2010, Hepatology.

[15]  S. Caldwell.  Cryptogenic Cirrhosis: What Are We Missing? , 2010, Current gastroenterology reports.

[16]  R. Ross,et al.  Effect of exercise training on cardiometabolic risk markers among sedentary, but metabolically healthy overweight or obese post-menopausal women with elevated blood pressure. , 2009, Atherosclerosis.

[17]  K. Cusi.  Role of insulin resistance and lipotoxicity in non-alcoholic steatohepatitis. , 2009, Clinics in liver disease.

[18]  L. J. Hardies,et al.  Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis , 2009, Hepatology.

[19]  B. S. Mohammed,et al.  Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity , 2009, Proceedings of the National Academy of Sciences.

[20]  C. Hellerbrand,et al.  Lipid accumulation in hepatocytes induces fibrogenic activation of hepatic stellate cells , 2009, Cell Research.

[21]  Steven R Smith,et al.  Early-life origins of metabolic dysfunction: role of the adipocyte , 2009, Trends in Endocrinology & Metabolism.

[22]  J. Ye.  Emerging role of adipose tissue hypoxia in obesity and insulin resistance , 2009, International Journal of Obesity.

[23]  B. Spiegelman,et al.  A Functional Peroxisome Proliferator-activated Receptor-γ Ligand-binding Domain Is Not Required for Adipogenesis* , 2008, Journal of Biological Chemistry.

[24]  G. Sesti,et al.  Insulin Secretion in Metabolically Obese, but Normal Weight, and in Metabolically Healthy but Obese Individuals , 2008, Obesity.

[25]  Peter Tontonoz,et al.  Fat and beyond: the diverse biology of PPARgamma. , 2008, Annual review of biochemistry.

[26]  B. S. Mohammed,et al.  Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects. , 2008, Gastroenterology.

[27]  A. Carpentier.  Postprandial fatty acid metabolism in the development of lipotoxicity and type 2 diabetes. , 2008, Diabetes & metabolism.

[28]  J. Baillargeon,et al.  Impaired plasma nonesterified fatty acid tolerance is an early defect in the natural history of type 2 diabetes. , 2008, The Journal of clinical endocrinology and metabolism.

[29]  Rena R Wing,et al.  Fitness, fatness, and cardiovascular risk factors in type 2 diabetes: look ahead study. , 2007, Medicine and science in sports and exercise.

[30]  Amalia Gastaldelli,et al.  Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. , 2007, Gastroenterology.

[31]  F. Anania,et al.  Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease. , 2007, Gastroenterology.

[32]  J. Hardies,et al.  A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. , 2006, The New England journal of medicine.

[33]  E. Parks,et al.  Contributions of different fatty acid sources to very low-density lipoprotein-triacylglycerol in the fasted and fed states. , 2006, The Journal of clinical endocrinology and metabolism.

[34]  F. Anania,et al.  The roles of leptin and adiponectin: a novel paradigm in adipocytokine regulation of liver fibrosis and stellate cell biology. , 2005, The American journal of pathology.

[35]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[36]  G. Wilcox.  Insulin and insulin resistance. , 2005, The Clinical biochemist. Reviews.

[37]  E. Ferrannini,et al.  Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms , 2005, Diabetologia.

[38]  R. DeFronzo,et al.  A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. , 2003, Diabetes.

[39]  Z. Bloomgarden,et al.  Inflammation and insulin resistance. , 2003, Diabetes care.

[40]  D. Crabb,et al.  Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. , 2002, Gastroenterology.

[41]  E. Ravussin,et al.  Increased Fat Intake, Impaired Fat Oxidation, and Failure of Fat Cell Proliferation Result in Ectopic Fat Storage, Insulin Resistance, and Type 2 Diabetes Mellitus , 2002, Annals of the New York Academy of Sciences.

[42]  G. Marchesini,et al.  Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. , 2001, Diabetes.

[43]  J. Clore,et al.  Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. , 2001, Gastroenterology.

[44]  C. Kahn,et al.  Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. , 2000, The Journal of clinical investigation.

[45]  R. DeFronzo,et al.  Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. , 1996, The Journal of clinical endocrinology and metabolism.

[46]  R N Pierson,et al.  How useful is body mass index for comparison of body fatness across age, sex, and ethnic groups? , 1996, American journal of epidemiology.

[47]  L. Groop,et al.  Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance. , 1989, The Journal of clinical investigation.

[48]  R. DeFronzo,et al.  Glucose clamp technique: a method for quantifying insulin secretion and resistance. , 1979, The American journal of physiology.